caprotec bioanalytics GmbH is a Berlin?based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri?functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples in solution. After isolation, the captured proteins including membrane proteins are identified by mass spectrometry. Providing a state?of?the?art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of protein biomarkers. The technology is protected by a broad patent portfolio. The company is supported by an international scientific advisory board including one Nobel Laureate.